维普期刊资源整合服务平台（V6.5）

76篇 您的检索式：作者名="Talpaz H"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Dasatinib用于治疗对伊马替尼耐药的Ph染色体阳性白血病显示文摘	Talpaz M Shah NP Kantarjian H 菅鑫妍	2006	中国处方药2006，5，8：	12
2	Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias 显示文摘	TALPAZ M SHAH N P KANTARJIAN H	2006	New Eng JMed2006，354，24：	1
3	New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance显示文摘	KANTARJIAN H M TALPAZ M GILES F	2006	Ann Intern Med2006，145，：	1
4	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosomepositive chronic myeloid leukemia显示文摘	Kantarjian H Talpaz M O'Brien S	2004	Blood2004，103，：	1
5	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase 显示文摘	SNEED T B KANTARJIAN H M TALPAZ M	2004	Cancer2004，100，：	1
6	New insights into thepathophysiology of chronic myeloid leukemia and imatinib resistance显示文摘	Kantarjian H M Talpaz M Giles F	2006	Annals of internal medicine2006，145，12：	1
7	Cellular signaling pathways: new targets in leukaemia therapy显示文摘	Ravandi F Talpaz M Kantarjian H	2002	Br J Haematol2002，116，1：	1
8	显示文摘	Druker B Kantarjian H Talpaz M	2002	Blood2002，99，：	1
9	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase显示文摘	Sneed T B Kantarjian H M Talpaz M	2004	Cancer2004，100，1：	1
10	A macroscopic scale model of water uptake by a nonuniform mot system and salt movement in the soil Profile 显示文摘	HILLEL D TALPAZ H KEULEN H	1976	Soil Science1976，121，4：	1
11	Dasatinib imatinibresistant philadelphia chromsome-positive leukemias 显示文摘	Talpaz M Shab N Kantarjian H	2006	N Engl J Med2006，10，：	1
12	Cyclophosphamide(CTX), Ara C, and topotecan (top) (CAT) for patients with chronic myelogenous leukemia(CML) in transformation显示文摘	Cortes J Kantarjian H Talpaz M	1998	Blood1998，92，1：	1
13	Expression of throm- bopoietin and its receptor(c-mpl) in chronic myelogenous leu-kemia: correlation with disease progression and response to therapy显示文摘	Kaban K Kantarjian H Talpaz M	2001	Cancer2001，88，3：	1
14	Chronic myelogenous leukemia:are view显示文摘	Cortes JE Talpaz M Kantarjian H	1996	Am J Med1996，100，5：	1
15	Model of plasma calcium regulation:system oscillations induces by growth显示文摘	HURWITZ S FISHMAN S TALPAZ H	1987	American Journal of Physiology1987，252，：	1
16	Calcium dy- namica : a model system approach 显示文摘	HURWITZ S FISHMAN S TALPAZ H	1987	The Journal of Nutrition1987，117，：	1
17	Dasatinib in imatinibresistant philadelphia chromosome-positive leukemias 显示文摘	Talpaz M Shah NP Kantarjian H	2006	N Engl J Med2006，354，24：	1
18	Chronic myelogenous leukemia显示文摘	Kantarjian H M Talpaz M	1999	Oneology1999，13，：	1
19	Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias 显示文摘	Talpaz M Shah NP Kantarjian H	2006	N Engl J Med2006，354，24：	1
20	Joint estimation of risk pref- erence structure and technology using expo - power utility 显示文摘	SAHA A SHUMWAY C R TALPAZ H	1994	A- merican Journal of Agricultural Economics1994，76，2：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示